<p>Mice were i.m. vaccinated with formalin inactivated RSV A2 (FI-A2) and then s.c. vaccinated with RSV A2 G peptide (FI-A2+G-A2) and control peptide (FI-A2 + L393). Two weeks following the final peptide boost, groups were challenged with live RSV A2 and the mean numbers of BAL cells/lung (A), total eosinophil counts in the BAL (B), IL-4 levels (pg/ml) (C) and IFN gamma (D) in the cell-free BAL supernatant, and viral message levels (relative genome equivalent PFU/ml) (E) at day 5 post-challenge (peak of cell infiltration) were determined. Representative data from five independent experiments are shown. * <i>p<0</i>.<i>05</i>.</p
<p>At day 4 post RSV infection, lung homogenates were prepared and the following were measured. (A) ...
<p>RSV-infected mice were treated with suboptimal doses of either anti-G mAb (130-6D, 150 µg/mouse) ...
<p>Mice (N = 7 per group) were immunized at days 0 and 14 with the indicated vaccines and challenged...
<p>(A) Total BAL cell counts in the lungs of mice i.m. vaccinated with FI-RSV A2 and live RSV A2 ch...
<p>Mice were i.m. vaccinated with formalin inactivated RSV A2, rested for at four weeks and i.n chal...
<p>Mice were vaccinated with 50 µg of RSV G nanoparticles, 10 µg of purified G protein emulsified 1:...
<p>Mice were i.m. vaccinated with formalin inactivated RSV A2 (FI-A2) and then s.c. vaccinated with ...
<p>Mice (n = 7 per group) were immunized at days 0 and 14 with the indicated vaccines and challenged...
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in ...
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in ...
<p>Groups of BALB/c mice were vaccinated with nanoparticle diluted in PBS to yield 50 µg of designed...
<p>Lung viral titers were determined from mice immunized with V1 or V5 VLPs and from FI-RSV immunize...
<p>(A) FI-mock- and FI-RSV-vaccinated mice were monitored daily for airway obstruction using a whole...
(A) Schematic representation of mouse immunization and challenge schedule. BALB/c mice (N = 6 per gr...
<p>Two weeks following the final boost and prior to RSV challenge, whole RSV A2 IgG specific titers ...
<p>At day 4 post RSV infection, lung homogenates were prepared and the following were measured. (A) ...
<p>RSV-infected mice were treated with suboptimal doses of either anti-G mAb (130-6D, 150 µg/mouse) ...
<p>Mice (N = 7 per group) were immunized at days 0 and 14 with the indicated vaccines and challenged...
<p>(A) Total BAL cell counts in the lungs of mice i.m. vaccinated with FI-RSV A2 and live RSV A2 ch...
<p>Mice were i.m. vaccinated with formalin inactivated RSV A2, rested for at four weeks and i.n chal...
<p>Mice were vaccinated with 50 µg of RSV G nanoparticles, 10 µg of purified G protein emulsified 1:...
<p>Mice were i.m. vaccinated with formalin inactivated RSV A2 (FI-A2) and then s.c. vaccinated with ...
<p>Mice (n = 7 per group) were immunized at days 0 and 14 with the indicated vaccines and challenged...
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in ...
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in ...
<p>Groups of BALB/c mice were vaccinated with nanoparticle diluted in PBS to yield 50 µg of designed...
<p>Lung viral titers were determined from mice immunized with V1 or V5 VLPs and from FI-RSV immunize...
<p>(A) FI-mock- and FI-RSV-vaccinated mice were monitored daily for airway obstruction using a whole...
(A) Schematic representation of mouse immunization and challenge schedule. BALB/c mice (N = 6 per gr...
<p>Two weeks following the final boost and prior to RSV challenge, whole RSV A2 IgG specific titers ...
<p>At day 4 post RSV infection, lung homogenates were prepared and the following were measured. (A) ...
<p>RSV-infected mice were treated with suboptimal doses of either anti-G mAb (130-6D, 150 µg/mouse) ...
<p>Mice (N = 7 per group) were immunized at days 0 and 14 with the indicated vaccines and challenged...